Cancer Screening and All-Cause Mortality: What Is the Benefit? is organized by Medscape, LLC.
CME / ABIM MOC / CE Released: 2/8/2019
Valid for credit through: 2/8/2020
Target Audience and Goal Statement
This article is intended for oncologists, family medicine/primary care practitioners, gastroenterologists, hematologists/oncologists, internists, nurses, pharmacists, and other members of the healthcare team involved in cancer screening.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
Evaluate the association between nonadherence to cancer screening tests and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening trial, after exclusion of mortality from these cancers
Assess the clinical implications of the association between nonadherence to cancer screening tests and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening trial, after exclusion of mortality from the cancers examined in this trial
Outline implications for the healthcare team
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
Additional details will be posted as soon as they are available.